Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Open accessAbstract
BACKGROUND: Angiotensin-converting-enzyme (ACE) inhibitors such as captopril reduce mortality and cardiovascular morbidity among patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients. METHODS: Patients receiving conventional therapy were randomly assigned, 0.5 to 10 days after acute myocardial infarction, to additional therapy with valsartan (4909 patients), valsartan plus captopril (4885 patients), or captopril (4909 patients). The primary end point was death from any cause. RESULTS: During a median follow-up of 24.7 months, 979 patients in the valsartan group died, as did 941 patients in the valsartan-and-captopril group and 958 patients in the captopril group (hazard ratio in the valsartan group as compared with the captopril group, 1.00; 97.5 percent confidence interval, 0.90 to 1.11; P=0.98; hazard ratio in the valsartan-and-captopril group as compared with the captopril group, 0.98; 97.5 percent confidence interval, 0.89 to 1.09; P=0.73). The upper limit of the one-sided 97.5 percent confidence interval for the comparison of the valsartan group with the captopril group was within the prespecified margin for noninferiority with regard to mortality (P=0.004) and with regard to the composite end point of fatal and nonfatal cardiovascular events (P<0.001). The valsartan-and-captopril group had the most drug-related adverse events. With monotherapy, hypotension and renal dysfunction were more common in the valsartan group, and cough, rash, and taste disturbance were more common in the captopril group. CONCLUSIONS: Valsartan is as effective as captopril in patients who are at high risk for cardiovascular events after myocardial infarction. Combining valsartan with captopril increased the rate of adverse events without improving survival.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Part of this paper’s reference list could not be split into single entries.
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 27
- Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transder- mal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
- ISIS-4 (Fourth International Study of In- farct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intra- venous magnesium sulphate in 58 050 pa- tients with suspected acute myocardial in- farction. Lancet 1995;345:669-85.
- Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13 634 patients with suspected acute myocar- dial infarction: interim report from the Chi- nese Cardiac Study (CCS-1). Lancet 1995; 345:686-7.
- Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting- enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial in- farction. N Engl J Med 1995;332:80-5.
- Swedberg K, Held P, Kjekshus J, Ras- mussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
- The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342: 821-8.
- Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-con- verting-enzyme inhibitor trandolapril in pa- tients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333:1670-6.
- Pfeffer MA. ACE inhibition in acute my- ocardial infarction. N Engl J Med 1995;332: 118-20.
- Flather MD, Yusuf S, Kober L, et al. Long- term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individu- al patients. Lancet 2000;355:1575-81.
- Goodfriend TL, Elliott ME, Catt KJ. An- giotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54.
- Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM, McMurray JJ. Angi- otensin converting enzyme (ACE) and non- ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001;37:1056-61.
- Horiuchi M, Akishita M, Dzau VJ. Re- cent progress in angiotensin II type 2 recep- tor research in the cardiovascular system. Hypertension 1999;33:613-21.
- Pfeffer MA, McMurray J, Leizorovicz A, et al. Valsartan in acute myocardial infarc- tion trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.
- Sidak Z. Rectangular confidence regions for the means of multivariate normal distri- butions. J Am Stat Assoc 1967;62:626-33.
- Hasselblad V, Kong DF. Statistical meth- ods for comparison to placebo in active- control trials. Drug Inf J 2001;35:435-49.
- Velazquez EJ, Pfeffer MA, McMurray JV, et al. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline char- acteristics in context. Eur J Heart Fail 2003; 5:537-44.
- Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Manage- ment of Heart Failure). J Am Coll Cardiol 2001;38:2101-13.
- Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60. [Erra- tum, Eur Heart J 2001;22:2217-8.]
- Skali H, Pfeffer MA. Prospects for ARB in the next five years. J Renin Angiotensin Aldosterone Syst 2001;2:215-8.
- Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. Br J Clin Pharmacol 2001;52:223-8.
- D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts The New England Journal of Medicine Downloaded from nejm.org on August 29, 2023. For personal use only. No other uses without permission. Copyright © 2003 Massachusetts Medical Society. All rights reserved. n engl j med 349;20
- www.nejm.org november 13, 2003 1906 valsartan, captopril, or both in myocardial infarction and issues -the encounters of academic consultants in statistics. Stat Med 2003;22: 169-86.
- Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsar- tan in chronic heart failure. N Engl J Med 2001;345:1667-75.
- Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart fail- ure: the CHARM-Overall Programme. Lan- cet 2003;362:759-66.
- Yusuf S. From the HOPE to the ONTAR- GET and the TRANSCEND studies: chal- lenges in improving prognosis. Am J Cardi- ol 2002;89:18A-25A.
- Dickstein K, Kjekshus J. Effects of losar- tan and captopril on mortality and morbidi- ty in high-risk patients after acute myocar- dial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
- Dickstein K. What did we learn from the OPTIMAAL trial? What can we expect from VALIANT? Am Heart J 2003;145:754-7.
Cited by
Sorted by citations
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536 · see citing works
Self-citationIbanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728 · see citing works
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391 · see citing works
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595 · see citing works
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502 · see citing works
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304 · see citing works
Self-citationYancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109 · see citing works
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862 · see citing works
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625 · see citing works
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644 · see citing works
Self-citationHeidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922 · see citing works
WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.167586 · Cited by 2,251 · see citing works
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759 · see citing works
Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cifkova, R., Clément, D., Coca, A., Dominiczak, A., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e328333146d · Cited by 1,643 · see citing works
Chronic Kidney Disease: Effects on the Cardiovascular System
Schiffrin, E. L., Lipman, M. L., & Mann, J. F. E. (2007) · Circulation · doi:10.1161/circulationaha.106.678342 · Cited by 1,448 · see citing works
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319 · see citing works
Self-citationAcute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association
Mehta, L. S., Beckie, T. M., DeVon, H. A., Grines, C. L., Krumholz, H. M., Johnson, M. N., Lindley, K. J., Vaccarino, V., Wang, T. Y., Watson, K. E., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000351 · Cited by 1,244 · see citing works
A Dynamic Pathway for Calcium-Independent Activation of CaMKII by Methionine Oxidation
Erickson, J. R., Joiner, M.-L. A., Guan, X., Kutschke, W., Yang, J., Oddis, C. V., Bartlett, R. K., Lowe, J. S., O'Donnell, S. E., Aykin-Burns, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.02.048 · Cited by 1,122 · see citing works
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000596 · Cited by 1,127 · see citing works
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
Barnett, A. H., Bain, S. C., Bouter, P., Karlberg, B., Madsbad, S., Jervell, J., & Mustonen, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042274 · Cited by 910 · see citing works
Healey, J. S., Baranchuk, A., Crystal, E., Morillo, C. A., Garfinkle, M., Yusuf, S., & Connolly, S. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.11.070 · Cited by 822 · see citing works
Ezekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., Giannetti, N., Grzeslo, A., Hamilton, P. G., Heckman, G. A., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.08.022 · Cited by 676 · see citing works
Solomon, S. D., Dobson, J., Pocock, S., Skali, H., McMurray, J. J. V., Granger, C. B., Yusuf, S., Swedberg, K., Young, J. B., Michelson, E. L., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.696906 · Cited by 681 · see citing works
Self-citationEffect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660 · see citing works
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639 · see citing works
Konstam, M. A., Neaton, J. D., Dickstein, K., Drexler, H., Komajda, M., Martinez, F. A., Riegger, G. A., Malbecq, W., Smith, R. D., Guptha, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61913-9 · Cited by 646 · see citing works
Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system
Palmer, B. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035279 · Cited by 640 · see citing works
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625 · see citing works
Gradman, A. H., Schmieder, R. E., Lins, R. L., Nussberger, J., Chiang, Y., & Bedigian, M. P. (2005) · Circulation · doi:10.1161/01.cir.0000156466.02908.ed · Cited by 521 · see citing works
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II
Beckman, J. A., Paneni, F., Cosentino, F., & Creager, M. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht142 · Cited by 434 · see citing works
Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., Deal, B. J., Dickfeld, T., Field, M. E., Fonarow, G. C., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000548 · Cited by 412 · see citing works
Aging and disease as modifiers of efficacy of cell therapy
Dimmeler, S., & Leri, A. (2008) · Circulation Research · doi:10.1161/circresaha.108.175943 · Cited by 379 · see citing works
Hung, C.-L., Verma, A., Uno, H., Shin, S.-H., Bourgoun, M., Hassanein, A. H., McMurray, J. J., Velazquez, E. J., Kober, L., Pfeffer, M. A., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.044 · Cited by 305 · see citing works
Self-citationArnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304 · see citing works
McDonald, M., Virani, S., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Heckman, G. A., Howlett, J. G., Koshman, S. L., Lepage, S., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.01.017 · Cited by 287 · see citing works
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280 · see citing works
Makani, H., Bangalore, S., Desouza, K. A., Shah, A., & Messerli, F. H. (2013) · BMJ · doi:10.1136/bmj.f360 · Cited by 244 · see citing works
The renin–angiotensin–aldosterone system and glucose homeostasis
Luther, J. M., & Brown, N. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.006 · Cited by 185 · see citing works
Makani, H., Messerli, F. H., Romero, J., Wever-Pinzon, O., Korniyenko, A., Berrios, R. S., & Bangalore, S. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.03.034 · Cited by 175 · see citing works
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145 · see citing works
Damman, K., Tang, W. H. W., Felker, G. M., Lassus, J., Zannad, F., Krum, H., & McMurray, J. J. V. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.031 · Cited by 122 · see citing works
Self-citationCatalá-López, F., Macías Saint-Gerons, D., González-Bermejo, D., Rosano, G. M., Davis, B. R., Ridao, M., Zaragoza, A., Montero-Corominas, D., Tobías, A., de la Fuente-Honrubia, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001971 · Cited by 109 · see citing works
Murphy, D. P., Drawz, P. E., & Foley, R. N. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018100971 · Cited by 106 · see citing works
Impact of hypertension and renin–angiotensin system inhibitors in aortic stenosis
Capoulade, R., Clavel, M., Mathieu, P., Côté, N., Dumesnil, J. G., Arsenault, M., Bédard, É., & Pibarot, P. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12169 · Cited by 97 · see citing works
Hospital performance measures and 30-day readmission rates
Stefan, M. S., Pekow, P. S., Nsa, W., Priya, A., Miller, L. E., Bratzler, D. W., Rothberg, M. B., Goldberg, R. J., Baus, K., & Lindenauer, P. K. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2229-8 · Cited by 95 · see citing works
Demers, C. (2005) · JAMA · doi:10.1001/jama.294.14.1794 · Cited by 78 · see citing works
Khan, S. S., Breathett, K., Braun, L. T., Chow, S. L., Gupta, D. K., Lekavich, C., Lloyd-Jones, D. M., Ndumele, C. E., Rodriguez, C. J., Allen, L. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001307 · Cited by 75 · see citing works
Best Strategies for Hypertension Management in Type 2 Diabetes and Obesity
Allcock, D. M., & Sowers, J. R. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0100-z · Cited by 35 · see citing works
Liao, S.-Y., Tse, H.-F., Chan, Y.-C., Mei-Chu Yip, P., Zhang, Y., Liu, Y., & Li, R. A. (2013) · Heart Rhythm · doi:10.1016/j.hrthm.2012.10.008 · Cited by 26 · see citing works
- Authors
- Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., Leimberger, J. D., Henis, M., Edwards, S., Zelenkofske, S., Sellers, M. A., & Califf, R. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Duke Medical Center (US)
- Montreal Heart Institute (CA)
- Rigshospitalet (DK)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- Sahlgrenska University Hospital (SE)
- Greenlane Clinical Centre (NZ)
- Novartis (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-11-13
- Volume
- 349
- Issue
- 20
- Pages
- 1893-1906
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168907840
- Cited by
- 2,471
- References
- 1
- Citations by year
- 2026: 19 · 2025: 38 · 2024: 55 · 2023: 53 · 2022: 60 · 2021: 48 · 2020: 68 · 2019: 57 · 2018: 62 · 2017: 88 · 2016: 98 · 2015: 91 · 2014: 98 · 2013: 124 · 2012: 123
- FWCI
- 117.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- valsartan, captopril, myocardial infarction, heart failure, left ventricular systolic dysfunction, ACE inhibitors, angiotensin receptor blockers, combination therapy, mortality, cardiovascular events, non-inferiority, adverse drug reactions, renal dysfunction, hypotension, cough, taste disorders, post-infarction therapy, secondary prevention
- MeSH terms
- Valsartan, Aged, Angiotensin-Converting Enzyme Inhibitors, Captopril, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Heart Failure, Humans, Male, Middle Aged, Myocardial Infarction, Tetrazoles, Valine, Ventricular Dysfunction, Left, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
